NASDAQ: SOPHSophia Genetics Sa Stock
$3.05-0.11 (-3.48%)
Updated Apr 30, 2025
SOPH Price
$3.05
Fair Value Price
N/A
Market Cap
$203.40M
52 Week Low
$2.58
52 Week High
$6.28
P/E
-3.21x
P/B
2.11x
P/S
3.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.17M
Earnings
-$62.49M
Gross Margin
67.4%
Operating Margin
-91.08%
Profit Margin
-95.9%
Debt to Equity
0.61
Operating Cash Flow
-$44M
Beta
1.05
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SOPH Overview
SOPHiA GENETICS SA is a healthcare technology company. It offers the SOPHiA DDM platform, a cloud-based SaaS platform that standardizes, computes, and analyzes digital health data across decentralized locations to break down data silos. Its solutions are used by hospitals, laboratories, and biopharmaceutical companies worldwide. SOPHiA GENETICS was incorporated in 2011 and is headquartered in Saint-Sulpice, CH.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SOPH's potential to beat the market
- SOPH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
SOPH
RankedUnranked of 45
RankedUnranked of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $109.97 | A | |
| $26.03 | A | |
| $4.63 | B |
Be the first to know about important SOPH news, forecast changes, insider trades & much more!
SOPH News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SOPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SOPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SOPH is good value based on its book value relative to its share price (2.11x), compared to the US Health Information Services industry average (3.52x)
P/B vs Industry Valuation
SOPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SOPH due diligence checks available for Premium users.
Valuation
SOPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.21x
Industry
40.3x
Market
29.18x
SOPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.11x
Industry
3.52x
SOPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SOPH's financial health
Profit margin
Revenue
$17.7M
Net Income
-$15.2M
Profit Margin
-85.5%
SOPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SOPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$155.3M
Liabilities
$58.8M
Debt to equity
0.61
SOPH's short-term assets ($99.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SOPH's short-term assets ($99.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SOPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SOPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.5M
Investing
-$1.9M
Financing
-$573.0k
SOPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SOPH vs Health Information Service Stocks
Sophia Genetics Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.